Growth Opportunity Fulgent Oncology operates under Fulgent Genetics with CSI Laboratories and Inform Diagnostics, suggesting potential cross-sell of broader genomics and diagnostic services to expand account coverage within the same corporate family.

Private Sector Focus With 51-200 employees and revenue in the 50-100 million range, the company is mid-sized and may be open to scalable, cost-effective partnerships, managed services, and value-based pricing models for diagnostic work.

Security Maturity Historical phishing and data breach incidents indicate heightened emphasis on cybersecurity; there is opportunity to propose advanced data protection, identity and access management, and breach-response services to strengthen trust with customers.

Tech Stack Alignment Current tech stack includes AWS, OneTrust, Microsoft 365, Salesforce Marketing Cloud, KnowBe4, and web technologies; sales engagements can tailor proposals leveraging these platforms for seamless integrations, data workflows, and customer communications.

Geographic Reach Operations across the United States and Caribbean imply a regional focus with potential for expansion into additional markets; sales efforts can target scalable lab services, regulatory-compliant logistics, and partnerships to support growth in new territories.